[1]
Hasan, K.M., Elmeshhadany, A.Y. and Shabila, N.P. 2022. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis. Sultan Qaboos University Medical Journal. 22, 3 (Aug. 2022), 393–399. DOI:https://doi.org/10.18295/squmj.8.2021.110.